ArticleBreast care (Basel, Switzerland)2016
HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.
Article in Breast care (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- HER2-positive neuroendocrine breast carcinoma: a case study uncoversPathologica · 2025Article
- Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.Frontiers in medicine · 2025Article
- Neuroendocrine neoplasms of the breast: a review of literature.Virchows Archiv : an international journal of pathology · 2024Review
- Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives.Frontiers in oncology · 2022Review
- HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: A case report and review of literature.Frontiers in oncology · 2022Review
- Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.Cancers · 2021Review
- Rare Human Epidermal Growth Factor Receptor 2 (HER-2)-Positive Neuroendocrine Carcinoma of the Breast: A Case Report with 9-Year Follow-up.The American journal of case reports · 2020Article
- Neuroendocrine breast carcinoma: a rare but challenging entity.Medical oncology (Northwood, London, England) · 2020Review
- Neuroendocrine Cancer of the Breast: A Rare Entity.Journal of clinical medicine · 2020Review
- Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues.Frontiers in endocrinology · 2020Review
- Classification of Widely and Rarely Expressed Genes with Recurrent Neural Network.Computational and structural biotechnology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine carcinoma is an uncommon histology for breast cancer. CASE REPORT: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.